Richard Geary
Corporate Officer/Principal at IONIS PHARMACEUTICALS, INC.
Net worth: 4 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Brett Monia | M | 62 | 35 years | |
| D. Walke | M | 58 | 8 years | |
| Patrick O'Neil | M | 50 | 23 years | |
| Joseph Loscalzo | M | 72 | 10 years | |
| B. Parshall | F | 70 | 33 years | |
| Elizabeth Hougen | F | 62 | 24 years | |
| Michael Hayden | M | 72 | 6 years | |
| Joseph Baroldi | M | 46 | 14 years | |
| Allene Diaz | F | 59 | 3 years | |
| Kim Doan | F | - | 9 years | |
| Spencer Berthelsen | M | 71 | 22 years | |
| C. Bennett | M | 67 | 35 years | |
| Joseph Wender | M | 79 | 30 years | |
| Joseph Klein | M | 62 | 19 years | |
| Joan Herman | F | 70 | 5 years | |
| Frank Rigo | M | - |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Annemieke Aartsma-Rus | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Shalini Andersson | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Steven Dowdy | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Paloma H. Giangrande | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Eric P. Bastings | M | - | 2 years | |
| Jonathan K. Watts | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Matt Buck | M | - | 19 years | |
| Dave Ecker | M | - | - | |
| Dawn Henson | F | - | 4 years | |
| Max Moore | M | - | - | |
| Tracy Berns | F | - | - | |
| Jeffrey Foy | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Shannon Devers | F | - | 15 years | |
| Leigh M. McAlister | M | 74 |
The University of Texas at Austin
| 38 years |
| Joel Ekstorm | M | - | - | |
| Darren Gonzales | M | - | 4 years | |
| Eric Swayze | M | - | 30 years | |
| Kyle Jenne | M | 48 | - | |
| Laura Sepp-Lorenzino | M | 63 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Jonathan Sessler | M | 68 |
The University of Texas at Austin
| 40 years |
| Isabel Aznarez | M | 52 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | 5 years |
| Michael Yang | M | 62 | 1 years | |
| Eugene Schneider | M | - | - | |
| Takanori Yokota | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Marc M. Lemaître | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Sanjay Bhanot | M | - | 24 years | |
| Kenneth B. Newman | M | 66 | - | |
| Ian MacLachlan | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | - |
| Marie Wikström Lindholm | M | - |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stanley Crooke | M | 78 | 32 years | |
| Donald E. Moss | M | 79 |
The University of Texas at Austin
| 10 years |
| John T. Ritter | M | - |
The University of Texas at Austin
| 7 years |
| Lance J. Rosmarin | M | 59 |
The University of Texas at Austin
| 7 years |
| Robert Carter Overton | M | - |
The University of Texas at Austin
| 6 years |
| Steven T. Baron | M | - |
The University of Texas at Austin
| 6 years |
| Mel S. Carter | M | - |
The University of Texas at Austin
| 7 years |
| Duane King | M | 63 |
The University of Texas at Austin
| 7 years |
| Ragheed Najeeb Shanti | M | - |
The University of Texas at Austin
| 6 years |
| Chris Bafo | M | - |
The University of Texas at Austin
| 6 years |
| Allen H. Kupetz | M | - |
The University of Texas at Austin
| 3 years |
| Ananth Dodabalapur | M | - |
The University of Texas at Austin
| 4 years |
| Diana Walters | F | 60 |
The University of Texas at Austin
| 5 years |
| Audrey T. Andrews | F | 57 |
The University of Texas at Austin
| 6 years |
| Stanley Bould | M | - |
The University of Texas at Austin
| 7 years |
| Brad Vaughn | M | - |
The University of Texas at Austin
| 7 years |
| Onaiza Cadoret-Manier | F | 60 | 4 years | |
| H. Hays Lindsley | M | 65 |
The University of Texas at Austin
| 7 years |
| Tom Wilkinson | M | 55 |
The University of Texas at Austin
| 6 years |
| David Ryan Druley | M | - |
The University of Texas at Austin
| 18 years |
| Thomas J. Murphy | M | - |
The University of Texas at Austin
| 5 years |
| Yu Chung Cho | M | 55 |
The University of Texas at Austin
| 5 years |
| Chase Robison | M | - |
The University of Texas at Austin
| 10 years |
| Joshua Patterson | M | 48 | 12 years | |
| Roslyn Patterson | F | - | 5 years | |
| Buddie Cloys Ballard | M | - |
The University of Texas at Austin
| 4 years |
| Bryan Willson | M | - |
The University of Texas at Austin
| - |
| Alex Stephen Trevino | M | 61 |
The University of Texas at Austin
| 6 years |
| Alan D. Green | M | 59 |
The University of Texas at Austin
| 4 years |
| Marcia Rosenbaum | M | 61 |
The University of Texas at Austin
| 6 years |
| Dan Kisner | M | 77 | 8 years | |
| David J. Ecker | M | 69 | 19 years | |
| Barrett Rouse | M | - |
The University of Texas at Austin
| 6 years |
| Frederick Muto | M | 70 | 21 years | |
| John Reed | M | 65 | 11 years | |
| Russell Kampfe | M | - |
The University of Texas at Austin
| 4 years |
| Brent Douglas Mellum | M | - |
The University of Texas at Austin
| 6 years |
| Susanne Gealy | F | - |
The University of Texas at Austin
| 5 years |
| Franklin Ruben | M | - |
The University of Texas at Austin
| 7 years |
| Peter N. Reikes | M | 63 | 3 years | |
| Thomas Fallon | M | 62 |
The University of Texas at Austin
| 7 years |
| Breaux B. Castleman | M | 83 | 8 years | |
| David E. Schwartz | M | - |
The University of Texas at Austin
| 7 years |
| Robert L. Hargett | M | - |
The University of Texas at Austin
| 7 years |
| Gabriela Franco Parcella | F | 55 |
The University of Texas at Austin
| 5 years |
| Lisa Stephens | F | - |
The University of Texas at Austin
| 5 years |
| Eric Reehl | M | 63 |
The University of Texas at Austin
| 5 years |
| Sudhir Joshi | M | - |
The University of Texas at Austin
| 3 years |
| Robert H. Scofield | M | - |
The University of Texas at Austin
| 3 years |
| Mike Salas | M | - |
The University of Texas at Austin
| 4 years |
| Scott Prochazka | M | 58 |
The University of Texas at Austin
| 4 years |
| Paul Raymond | M | 61 |
The University of Texas at Austin
| 3 years |
| Thomas D. Williams | M | 63 |
The University of Texas at Austin
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Geary
- Personal Network
